61686-61-1 Usage
Uses
Used in Pharmaceutical Industry:
N-((5-bromopyridin-3-yl)methyl)aniline is used as an intermediate in the synthesis of various pharmaceuticals. Its unique structure allows it to be a building block for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
N-((5-bromopyridin-3-yl)methyl)aniline is also utilized in the agrochemical industry, where it serves as a precursor in the production of various agrochemicals. Its properties can contribute to the effectiveness of these products in agricultural applications.
Used in Organic Material Synthesis:
N-((5-bromopyridin-3-yl)methyl)aniline is used as a building block for the production of dyes, pigments, and other organic compounds. Its presence in these materials can enhance their color, stability, or other desired properties.
Used in Chemical Industry:
The bromine and pyridine groups in N-((5-bromopyridin-3-yl)methyl)aniline make it a versatile compound for use in the chemical industry. It can be employed in various chemical processes to create a range of products with specific chemical and physical characteristics.
Check Digit Verification of cas no
The CAS Registry Mumber 61686-61-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,1,6,8 and 6 respectively; the second part has 2 digits, 6 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 61686-61:
(7*6)+(6*1)+(5*6)+(4*8)+(3*6)+(2*6)+(1*1)=141
141 % 10 = 1
So 61686-61-1 is a valid CAS Registry Number.
61686-61-1Relevant academic research and scientific papers
KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE
-
Paragraph 0154; 0170, (2022/01/04)
Disclosed herein are kinase inhibitor compounds having the structure (I) or a stereoisomer, pharmaceutically acceptable salt, oxide, or solvate thereof, where R1, R2, X, L, Q, and Y are as defined herein. Also disclosed are compositions containing the kinase inhibitor compounds, methods of inhibiting activity of a kinase in a cell, methods of increasing cell proliferation in a population of pancreatic beta cells, methods of treating a subject for a condition associated with insufficient insulin secretion, and methods of treating a subject for a neurological disorder.
KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE
-
Paragraph 0177; 0259, (2020/07/21)
Disclosed herein are kinase inhibitor compounds having structure (I), or a stereoisomer, pharmaceutically acceptable salt, oxide, or solvate thereof, where R1, R2, R3, R4, R5, R6, R7, X, Y, Z, and (AA) are as defined herein. Also disclosed are compositions containing the kinase inhibitor compounds, methods of inhibiting activity of a kinase in a cell, methods of increasing cell proliferation in a population of pancreatic beta cells, methods of treating a subject for a condition associated with insufficient insulin secretion, and methods of treating a subject for a neurological disorder.
